Psoriatic arthritis. Psoriasis is known for causing itchy skin and rashes, but this autoimmune disease also harms joints. People with psoriatic arthritis usually experience skin problems before their joints become inflamed. This can cause permanent joint damage if untreated. Infectious arthritis. Also kn...
Research interest is high around the newest biological drugs approved for the treatment of moderate to severe psoriasis and psoriatic arthritis, and especially drugs blocking the IL/IL axis. Our aim is to review the new biological drugs for the treatment of psoriasis and their adverse effects, ...
More than 80 patients with psoriasis orpsoriatic arthritis(termed psoriatic disease) at four different dermatology and rheumatology practices across the United States were enrolled in the pilot program. During the course of a year, participants received blood tests to measures their lipids and hemoglobin...
I have studied and treated ankylosing spondylitis (AS) for almost 10 years. It’s a form of axial spondyloarthritis (axSpA). That’s a type of inflammatory arthritis that primarily affects the spine and the sacroiliac (SI) joints that connect the lower spine to the pelvis. In its early sta...
Psoriasis is a common immune-mediated disease of the skin, which associates in 20-30% of patients with psoriatic arthritis (PsA). The immunopathogenesis of... F Villanova,PD Meglio,FO Nestle - 《Annals of the Rheumatic Diseases》 被引量: 123发表: 2013年 Newly available treatments for psoriati...
However, with the recent exception of the biologic drugs for treatment of psoriasis, the products that are somewhat exclusive to dermatology rarely command annual sales of over $100 million. In fact, most of these drugs have annual sales below the $50 million mark.2 Regarding the biologic ...
arthritis, myalgias and serositis, although cutaneous manifestations have been reported in association with the use of tumor necrosis factor inhibitors. Typically, clinical features resolve with discontinuation of the medication, although antibodies can persist for months or years. Arthralgias and inflamma...
(Reis et al.2019). The efficacy of bimekizumab has been substantiated through the American College of Rheumatology response criteria and the Psoriasis Area and Severity Index, demonstrating consistent maintenance from week 16 to week 52 of treatment (Ritchlin et al.2023). In another clinical ...
Another indication than plaque psoriasis as the main indication for biologic use (e.g., psoriatic arthritis). Concomitant use of systemic immunosuppressants other than methotrexate or acitretin. Severe comorbidities with short life-expectancy. Presumed inability to follow the study protocol....
A medication used for psoriasis and psoriatic arthritis is proving to be an effective treatment for moderate to severe ulcerative colitis in the findings of a global study led by University of Chicago Medicine's David T. Rubin, MD, Professor of Medicine and Chief of the Section of Gastroenterolo...